辽东楤木叶总皂苷体外抗肿瘤作用的研究

目的探讨辽东楤木叶总皂苷(ETS)的体外抗肿瘤作用,为进一步将其开发成新靶点的抗肿瘤药物提供可靠的科学依据,为研发具有自主知识产权的抗肿瘤新药奠定坚实的基础。方法利用磺酰罗丹明B(SRB)染色法,观察辽东楤木叶总皂苷不同浓度对A549、BGC、BEL-7402和HCT-8肿瘤细胞的抑制作用。结果 ETS浓度达到31.25μg.ml-1时即可对人肺腺癌A549细胞、人胃癌BGC细胞和人肝癌BEL-7402细胞有50%生长抑制作用,达到62.5μg.ml-1时即可对人结肠癌HCT-8细胞有50%生长抑制作用。其浓度达到125μg.ml-1时即可对人胃癌BGC细胞和人肝癌BEL-7402细胞有50%杀死的作用。浓度达到500μg.ml-1时即可对人结肠癌HCT-8细胞有50%杀死的作用,而对人肺腺癌A549细胞未测出其50%杀死作用。各组均未测出完全抑制细胞生长所需的ETS浓度。对于体外加药48 h后对A549、BGC、BEL和HCT-8细胞OD值的影响,ETS组500,250,125μg.ml-1均有极显著性统计学差异(P<0.01),62.5μg.ml-1对A549、BEL和HCT-8均有显著性意义;31.25μg.ml-1均无统计学意义。结论 ETS体外对人肺癌A549、人胃癌BGC、人肝癌BEL-2、人结肠癌HCT-8肿瘤细胞有一定的抑制作用。     

具有双迈克尔受体结构单元的齐墩果酸衍生物的设计、合成及抗肿瘤活性

目的:设计、合成具有双迈克尔受体结构单元的齐墩果酸衍生物并研究其体外抗肿瘤活性。方法:以齐墩果酸为原料,经过酰化、酯化、水解、氧化以及醇醛缩合反应得到目标化合物;采用MTT法在白血病HL-60,肝癌SMMC-7721,肺癌A-549,乳腺癌MCF-7,结肠癌SW480细胞株上进行了体外抗肿瘤活性的测试。结果:合成了一个具有双迈克尔受体结构单元的新齐墩果酸衍生物,并经过1H-NMR,13C-NMR,ESI-MS确证了化学结构。结论:初步的体外抗肿瘤活性显示,该化合物具有较好的抗肿瘤活性,在结肠癌SW480细胞株上较为明显。     

青蒿素类药对A549和Hela细胞体外抗肿瘤活性的研究

目的：研究青蒿素类药物对非小细胞肺癌A549和宫颈癌Hela细胞的体外抗肿瘤活性。方法：采用四甲基偶氮唑蓝（MTT）法测定青蒿素、双氢青蒿素及青蒿琥酯体外抑制人肺癌细胞和宫颈癌细胞的活性。结果：双氢青蒿素及青蒿琥酯对A549细胞72h的IC50为27．971μg／mL、43．90μg／mL；青蒿素、双氢青蒿素及青蒿琥酯对Hela细胞72h的Ic50分别为48．10μg／mL、15．94μg/mL、34．60μg／mL。结论：青蒿素、双氢青蒿素及青蒿琥酯对2株肿瘤细胞有选择性抑制作用。青蒿素类药物中，双氢青蒿素和青蒿琥酯抗肿瘤作用较好。     

肿节风注射液体外抗肿瘤作用的实验研究

目的：测定肿节风注射液（ZJF）体外对人肺癌A-549、结肠癌HCT-29、胃癌BGC-823的活性。方法：用细胞生长曲线法、MTT试验、形态学观察研究了肿节风注射液（ZJF）的体外抗肿瘤作用。结果：肿节风注射液（ZJF）对A-549、HCT-29、BGC-823三种人系肿瘤细胞均有较强的体外细胞毒作用，且呈浓度依赖性。结论：肿节风注射液（ZJF）具有体外抗肿瘤作用。     

楤木皂苷抗肿瘤活性研究

目的 研究楤木皂苷的体内外抗肿瘤作用.方法 以人红白血病细胞株K562、人肝癌细胞株HepG2、人结肠癌细胞株LOVO和人乳腺癌细胞株MDA-MB-231为模型,采用cell counting kit-8 (CCK-8)检测楤木皂苷的体外抗肿瘤活性;以小鼠肝癌H22和小鼠肉瘤S180为移植性肿瘤模型,检测楤木皂苷的体内抗肿瘤活性.结果 楤木皂苷可抑制K562、HepG2,LOVO和MDA-MB-231的增殖,其IC50值分别为(209.10±32.69),(273.30±20.40),(293.60±5.85),(329.67±26.42) mg · L-1,均大于30 mg · L-1;在50,100 mg·kg-1时,楤木皂苷对小鼠肝癌H22的抑瘤率分别为28.8%,47.06%,对小鼠肉瘤S180的抑瘤率分别为27.94%,54.92%.结论 楤木皂苷体外抗肿瘤活性弱,但体内抗肿瘤活性较强.     

灵芝乙醇提取物抗肿瘤活性研究

目的:探究灵芝乙醇提取物体内外抗肿瘤的活性。方法:体外实验:采用6种人肿瘤细胞系(胰腺癌SW1990、肺癌A549、宫颈癌Hela、肝癌Hep G2、胃癌MKN45、乳腺癌MCF-7),用灵芝乙醇提取物处理肿瘤细胞,观察细胞生长形态、绘制生长曲线、进行MTT实验及平板集落形成实验。体内实验:采用裸鼠胰腺癌SW1990移植瘤模型,以灵芝乙醇提取物50、100、150mg/kg剂量灌胃,计算瘤体积、抑瘤率及脏器系数。结果:体外实验:灵芝乙醇提取物对胰腺癌SW1990、肺癌A549、宫颈癌Hela、肝癌Hep G2、胃癌MKN45、乳腺癌MCF-7细胞的半数抑制率分别为96.62、44.21、78.66、117.60、44.34、73.28μg/ml。体内实验:70%灵芝提取物50、100、150mg/kg剂量组抑瘤率分别为37.2%、39.2%、43.9%。结论:体外实验表明灵芝乙醇提取物对上述6种肿瘤细胞均具有抑制增殖的作用,且浓度在40μg/ml以上时抑制增殖的作用较强。体内实验表明灵芝乙醇提取物能抑制胰腺癌SW1990生长。     

云南10种花的抗肿瘤活性研究

目的:探索云南花朵的抗肿瘤活性。方法:花朵烘干后磨成粉末,用乙醇提取后浓缩得花朵提取物。将体外培养的肿瘤细胞分成对照组和试验组,每组设6个复孔。用MTS法测试花朵提取物对乳腺癌MDA-MB-231细胞的抑制作用。将有对乳腺癌MDA-MB-231细胞增殖有较好抑制作用的花朵提取物进一步进行肿瘤活性测试。将该花朵提取物分为不同浓度,测试其对乳腺癌MDA-MB-231细胞和肺癌A549细胞的抑制活性。结果:在采集来的10种花朵中,葱莲对乳腺癌MDA-MB-231细胞具有较好的抑制活性,抑制率(43.07±4.52%)与阳性对照药物(47.62±3.24%)接近。进一步研究发现,葱莲对乳腺癌MDA-MB-231细胞和肺癌A549细胞均有抑制活性,并且呈剂量效应关系。结论:葱莲花朵提取物具有较好的抗肿瘤应用前景。     

藤黄酸对人结肠癌LOVO、SW480细胞端粒酶的抑制作用

目的探讨藤黄酸(GA)对人结肠癌LOVO、SW480细胞端粒酶的抑制作用及可能机制。方法用不同浓度的藤黄酸作用体外生长的人结肠癌LOVO、SW480细胞,采用CCK-8法检测两株细胞增殖抑制率,蛋白质印迹法(Western blot)检测两株细胞h TERT蛋白表达,实时荧光定量QRT-PCR法检测h TERT mRNA表达。结果藤黄酸对人结肠癌LOVO、SW480细胞具有显著抑制增殖作用,并呈现明显的浓度及时间依赖性(P0.05或P0.01);Western blot结果显示,藤黄酸能降低LOVO、SW480细胞h TERT蛋白的表达,且呈浓度依赖性(P0.05或P0.01);QRT-PCR测定显示,藤黄酸能降低LOVO、SW480细胞h TERTmRNA的表达,呈浓度依赖性(P0.05或P0.01)。结论藤黄酸能够显著抑制人结肠癌LOVO、SW480细胞的增殖,其机制可能是通过下调h TERT mRNA的表达而有效地抑制癌细胞端粒酶活性。     

丹参二萜醌部位高速逆流色谱制备工艺及体外抗肿瘤活性研究

目的优选分离丹参二萜醌最佳的高速逆流色谱(HSCCC)溶剂体系,明确丹参二萜醌的体外抗肿瘤活性。方法采用CO2超临界萃取法制备丹参总二萜醌,采用UPLC测定丹参酮IIA和隐丹参酮在不同溶剂系统上下相中的峰面积,计算分配系数(K)值及K值的比值(α),确定最佳溶剂体系。CKK-8法观察丹参二萜醌对人肝癌(QGY-7703)、肺癌(PC9、A549)、胃癌(MKN-45、HGC-27)、结肠癌(HCT116)、骨髓瘤(U266、RPMI8226)、乳腺癌(MCF-7)等9种人源肿瘤细胞株的抑制作用。结果 HSCCC溶剂系统为石油醚-醋酸乙酯-甲醇-水(12∶8∶13∶7)时,丹参酮IIA和隐丹参酮能得到较好的分离,丹参二萜醌的得率为8.65%。丹参二萜醌体外对人肝癌、肺癌、胃癌、结肠癌、骨髓瘤、乳腺癌等9种人源肿瘤细胞均有一定的抑制作用,其中对人肺癌PC9细胞及人乳腺癌MCF-7细胞的抑制作用最为显著。结论确定的溶剂体系对丹参二萜醌有效部位的分离效果可靠,建立的HSCCC制备方法操作简单,可作为高效快速分离纯化丹参二萜醌的分离制备方法。丹参二萜醌在体外具有良好的抗肿瘤活性。     

常用14种抗肿瘤中药体外抑瘤效果比较

目的:比较14种常用抗肿瘤中药的体外抑瘤效果。方法:采用四甲基偶氮唑兰(MTT)法分别测定了14种常用抗肿瘤中药的水提液、醇提液对人胃癌细胞株AGS、人胃癌细胞株BGC-823体外增殖反应的影响。结果:该14种中药中有10味体外对人胃癌细胞株AGS、人胃癌细胞株BGC-823体外增殖均有阳性抑制作用;且该10味中药醇提液体外对人胃癌细胞株AGS、人胃癌细胞株BGC-823体外增殖抑制作用优于水提液;有2味中药醇提浸膏对人胃癌细胞株AGS、人胃癌细胞株BGC-823体外增殖抑制作用均为强阳性;而其余2味中药对2株细胞抑制率为阴性。结论:14种中药中10味体外对胃癌细胞抑制率大于50%,但提取工艺对抑瘤效果存在较大影响,应尽量采用醇提工艺提取。     

益气补肾口服液体外抗肿瘤作用的实验研究

目的:研究益气补肾口服液的体外对SMMC-27721细胞及A-549细胞生长抑制作用。方法:采用活细胞计数法及MTT法观察益气补肾口服液对上述两种人瘤细胞进行检测和观察。结果:益气补肾口服液对上述两种人瘤细胞的生长增殖曲线具有明显的抑制作用。对两种人瘤细胞降解MTT半数抑瘤浓度(IC50)分别为1.02mg/mL、0.73mg/mL;对两种人瘤细胞的集落形成有明显的抑制作用,最大抑制率分别为78.48%、89.17%。结论:益气补肾口服液体外具有明显的抗肿瘤活性。     

Antitumour effects of phyllanthus emblica L.: Induction of cancer cell apoptosis and Inhibition of in vivo tumour promotion and in vitro invasion of human cancer cells

Phyllanthus emblica Linn. (PE) is a medicinal fruit used in many Asian traditional medicine systems for the treatment of various diseases including cancer. The present study tested the potential anticancer effects of aqueous extract of PE in four ways: (1) against cancer cell lines, (2) in vitro apoptosis, (3) mouse skin tumourigenesis and (4) in vitro invasiveness. The PE extract at 50–100 µg/mL significantly inhibited cell growth of six human cancer cell lines, A549 (lung), HepG2 (liver), HeLa (cervical), MDA‐MB‐231 (breast), SK‐OV3 (ovarian) and SW620 (colorectal). However, the extract was not toxic against MRC5 (normal lung fibroblast). Apoptosis in HeLa cells was also observed as PE extract caused DNA fragmentation and increased activity of caspase‐3/7 and caspase‐8, but not caspase‐9, and up‐regulation of the Fas protein indicating a death receptor‐mediated mechanism of apoptosis. Treatment of PE extract on mouse skin resulted in over 50% reduction of tumour numbers and volumes in animals treated with DMBA/TPA. Lastly, 25 and 50 µg/mL of PE extract inhibited invasiveness of MDA‐MB‐231 cells in the in vitro Matrigel invasion assay. These results suggest P. emblica exhibits anticancer activity against selected cancer cells, and warrants further study as a possible chemopreventive and antiinvasive agent. Copyright © 2010 John Wiley & Sons, Ltd.     

����Ƥ������������ȫ�˵���¡����Ranti-HER�Ŀ�����ҩ�������о�

??OBJECTIVE To observe the in vivo activity of Ranti-HER, a fully human monoclonal antibody, and combined with the doxorubicin or CPT-11 in established human tumor xenografts in nude mice, and to investigate whether EGFR expression is correlated with this activity. METHODS The overall receptor of EGF was quantified by flow cytometry. The anti-tumor effects of Ranti-HER were evaluated using established, s/c human carcinoma xenografts in nude mice, and the relative growth rate of tumor was used to assess the anti-tumor activity. RESULTS A431 cells showed highly expression of EGFR by flow cytometry, SW620 showed negative expression, and EGFR were expressed positively in HT29 and SW948 cells, but both of them were showed low expression. Ranti-HER(0.25-1.0 mg) could inhibit the tumor growth in human A431 epidermoid carcinoma xenografts and dose-effect relationship was observed; Ranti-HER(1.0 mg) could also inhibit the tumor growth in human SW948 colon carcinoma xenografts, but no anti-tumor effects of Ranti-HER 1.0 mg were observed in human HT29 and SW620 colon carcinoma xenografts. Therapeutic enhancement was observed in the A431 xenografts after treatment with Ranti-HER combined with doxorubicin. For another combination regimens, Ranti-HER and CPT-11 proved to be significantly more efficacious than Ranti-HER monotherpy in SW948 xenografts. CONCLUSION Anti-tumor activity of Ranti-HER are observed in xenografts in athymic nude mice, and the activity of Ranti-HER is correlated with the EGFR expression; synergistic effects are observed when Ranti-HER is combined with chemicals compared to Ranti-HER monotherapy.     

青蒿素类化合物抗肿瘤作用激活机制的研究进展

青蒿素类化合物是一类重要的抗疟疾药物,对大部分肿瘤细胞也有抑制作用,但对人正常组织细胞影响较小。研究表明,青蒿素作为前药被激活后的抗肿瘤效果更好。关于青蒿素的激活因素,目前的研究主要围绕亚铁离子、血红素和线粒体,但仍存在争议,不确定的激活因子使青蒿素在抗肿瘤方面的研究陷入瓶颈。总结了青蒿素类化合物在肿瘤细胞内相关激活因子的研究进展,包括对激活因子组成和功能的介绍,为深入研究青蒿素抗肿瘤作用机制提供依据和借鉴。     

��Ƥ��������ĺϳɼ��俹���������о�

??OBJECTIVE To design and synthesize series of quercetin derivatives by introducing allyl or prenyl groups and investigate their antitumor activities in vitro.METHODS Compounds 2, 3, 4, 5, 6, 7 and 8 were synthesized with quercetin as starting material through the etherification reaction.The antitumor activities were evaluated by MTT assay against human lung cells (A549), human breast cancer cells (MDA-MB-231), and human hepatoma cells (HepG2).RESULTS Two allyl-substituted and five prenyl-substituted quercetin derivatives were synthesized. Compounds 4, 5, 6, 7, and 8 were new compounds, and their structures were characterized by ¹H-NMR and ¹³C-NMR. Compounds 6 and 7 exhibited observable anti-proliferative activity. Compound 6 inhibited the growth of A549, MDA-MB-231, and HepG2 cells with IC₅₀ values of 15.23, 16.56, and 12.32 ??mol??L^-1, respectively.Compound 7 restrained the growth of A549 and MDA-MB-231 cells with IC₅₀ values of 8.92 and 2.90 ??mol??L^-1, respectively. CONCLUSION Compounds 6 and 7 synthesized by introducing prenyl groups into quercetin have significant anti-tumor activities, which are worth of further research.     

尼泊尔酸模中分离到的1个新萘酮类化合物

对尼泊尔酸模根的化学成分进行研究。综合运用多种色谱分离技术对尼泊尔酸模根的乙酸乙酯萃取物进行分离纯化,通过核磁共振和高分辨质谱等波谱学分析方法确定化合物的结构。该研究从尼泊尔酸模根中分离到1个新萘酮类化合物,命名为酸模酮A(1),并采用人肺癌细胞A549、人肝癌细胞HepG2、人胃癌细胞SGC7901、人乳腺癌细胞MDA-MB-231评价其体外细胞毒性。     

Extracts from the roots of Lindera strychifolia induces apoptosis in lung cancer cells and prolongs survival of tumor-bearing mice

Lindera strychifolia, a scandent shrub Lauraceous medicinal plant, has been used in Chinese traditional medicine as a palliative and an anti-spasmodic. It also shows cytotoxic effects against several tumor cell lines and inhibits marcromolecule biosynthesis. This study investigated the anti-tumor effects of L. strychifolia extract against lung cancer cells using in vitro and in vivo models. Two human lung cancer cell lines A549 (adenocarcinoma) and SBC-3 (small cell carcinoma), and a non-tumor cell line 3T3-L1 (mice fibroblasts) were subjected to L. strychifolia extract treatment. On lung cancer cells, L. strychifolia induced cell growth inhibition in a dose-dependent manner. Conversely, the extract did not show any significant cytotoxic effect on 3T3-L1 cells. Therefore, the extract is specific for tumor cells. Tumor cells treated with L. strychifolia extract showed typical morphological appearance of apoptosis including nuclei fragmentation and cell condensation. The in vivo effects of L. strychifolia extract were investigated in C57BL/6 mice transplanted with Lewis lung cancer (LL-2) cells, and in BALB/c nude mice transplanted with A549 or SBC-3 human lung cancer cells. Oral administration of L. strychifolia extract prolonged survival time and inhibited tumor growth in a dose-dependent manner by inducing apoptosis in the LL-2 cell mice model. Furthermore, in A549 or SBC-3 cell nude mice models, oral administration of L. strychifolia extract also significantly inhibited tumor growth at the 5.0 mg/ml concentration. These findings suggested that the components of L. strychifolia have anticancer activity and may contribute to clinical applications in the prevention and treatment of lung cancer.     

16-����˫ϩ��ͪ֬����������⿹���������о�

??OBJECTIVE To investigate the antitumor effect of 16-dehydropregnenolone(16-DHP) liposomes. METHODS Twelve kinds of tumor cells were used to determine the cytotoxic effect of 16-DHP liposome by MTT assay. The established tumor xenograft in nude mouse model was used to evaluate anti-tumor effect of 16-DHP liposomes after tail vein injection. RESULTS IC₅₀ value of 16-DHP liposomes to the human hepatoma cell HepG2, human oral carcinoma KB cell, human breast cancer T47D, human gastric cancer cell SGC7901, human fibrosarcoma cell HT1080, human ovarian cancer cell SKOV3,human prostate cancer cell PC3, human prostrate cancer cell DU145, human lung cancer cell A549, human rhabdomyosarcoma A204 cell and human cervical carcinoma cell HeLa were 44.69, 9.17,26.22, 19.58, 28.01, 37.18, 24.58, 21.38, 54.69,4.18 and 8.96 ??g??mL^-1, respectively. The relative tumor increment rate and inhibition rates of tumor weight were 93.7%, 60.52%, 37.84% and 23.05%,48.84%,69.70% respectively after treated with 16-DHP liposomes (7.5, 15 and 30 mg??kg^-1??d^-1 , 28 d). CONCLUSION 16-DHP liposomes possess in vitro and in vivo anti-tumor activities.
     

山核桃外果皮提取物抗肿瘤活性研究

目的研究山核桃外果皮抗肿瘤活性部位。方法利用系统溶剂分离法,对山核桃外果皮进行部位分离,采用MTT法分别检测水提取物、甲醇提取物、石油醚提取物、醋酸乙酯提取物对小鼠肺癌细胞3LL、人乳腺癌细胞MCF-7、人肝癌细胞QGY-7701、人胃癌细胞BGC-823等4种肿瘤细胞株的生长抑制情况。结果水提取物对上述肿瘤细胞抑制作用均不明显,甲醇和石油醚提取物对4种肿瘤细胞有抑制作用,醋酸乙酯提取物对4种肿瘤细胞有明显的抑制效果,且呈一定的浓度-效应关系。结论山核桃外果皮的甲醇提取物、石油醚提取物及醋酸乙酯提取物具有一定的体外抗肿瘤作用。     

粗吻海龙蛋白质组分体外抗肿瘤活性的研究

 目的探讨粗吻海龙水溶性蛋白质组分的抗肿瘤活性。方法应用四甲基偶氮唑盐法检测药物细胞毒效应,应用流式细胞术分析药物对A549细胞周期和凋亡率的变化,琼脂糖凝胶电泳、荧光显微镜观察药物对A549细胞凋亡和细胞周期相关性质改变。结果粗吻海龙蛋白对L1210、CCRF-CEM、A549、LOVO细胞的IC₅₀分为1.86,1.56,0.88,1.74 g·L^-1。粗吻海龙蛋白质组分对A549细胞作用表现出凋亡细胞特征性的改变,并能增强甲氨蝶呤、丝裂霉素对A549的细胞毒作用。结果粗吻海龙蛋白质组分对肿瘤细胞增生有明显的抑制作用,可引起肿瘤细胞凋亡。